TransMedics Group, Inc. (NASDAQ:TMDX) Shares Acquired by ProShare Advisors LLC

ProShare Advisors LLC lifted its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 62.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,064 shares of the company's stock after purchasing an additional 3,870 shares during the quarter. ProShare Advisors LLC's holdings in TransMedics Group were worth $627,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in TMDX. Arizona State Retirement System boosted its holdings in TransMedics Group by 1.9% in the fourth quarter. Arizona State Retirement System now owns 9,668 shares of the company's stock worth $603,000 after acquiring an additional 184 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its stake in shares of TransMedics Group by 7.2% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company's stock worth $294,000 after purchasing an additional 317 shares in the last quarter. Atlas Capital Advisors Inc. purchased a new stake in shares of TransMedics Group in the 4th quarter worth $31,000. Alliancebernstein L.P. raised its holdings in TransMedics Group by 1.2% in the 4th quarter. Alliancebernstein L.P. now owns 40,572 shares of the company's stock worth $2,530,000 after purchasing an additional 500 shares during the period. Finally, Venturi Wealth Management LLC lifted its position in shares of TransMedics Group by 58.0% during the 4th quarter. Venturi Wealth Management LLC now owns 1,373 shares of the company's stock valued at $86,000 after buying an additional 504 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Trading Down 0.5%

TMDX stock traded down $0.66 during trading on Friday, hitting $127.03. The company had a trading volume of 180,288 shares, compared to its average volume of 1,353,009. TransMedics Group, Inc. has a 52-week low of $55.00 and a 52-week high of $177.37. The company has a 50 day simple moving average of $94.15 and a 200-day simple moving average of $78.41. The firm has a market capitalization of $4.30 billion, a P/E ratio of 134.80 and a beta of 1.91. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.41. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. During the same period last year, the company posted $0.35 earnings per share. The company's quarterly revenue was up 48.2% compared to the same quarter last year. As a group, research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other news, Director Edward M. Basile sold 6,000 shares of TransMedics Group stock in a transaction on Friday, May 9th. The stock was sold at an average price of $115.63, for a total value of $693,780.00. Following the transaction, the director now directly owns 732 shares in the company, valued at approximately $84,641.16. This trade represents a 89.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director David Weill sold 732 shares of the company's stock in a transaction on Friday, May 23rd. The stock was sold at an average price of $123.88, for a total value of $90,680.16. Following the sale, the director now owns 12,134 shares of the company's stock, valued at $1,503,159.92. This trade represents a 5.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,732 shares of company stock valued at $1,416,710 in the last ninety days. Corporate insiders own 7.00% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on TMDX shares. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Canaccord Genuity Group reiterated a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Oppenheimer raised their price objective on TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a research note on Friday, May 9th. Finally, Piper Sandler reaffirmed an "overweight" rating and set a $125.00 price objective (up from $105.00) on shares of TransMedics Group in a research note on Friday, May 9th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $126.70.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.